CTOs on the Move

Swift Biosciences

www.swiftbiosci.com

 
Swift Biosciences is a biotechnology company that is developing novel molecular biology technologies to better characterize and understand the genome. We are an energetic, highly innovative company focused on creating tools to advance the DNA sequencing sciences. Our products are designed to help customers analyze challenging samples that are often associated with translational work, including circulating, cell-free DNA and formalin-fixed, paraffin-embedded samples.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Swift Biosciences raised $12.2M on 06/30/2017

Similar Companies

DNA SOLUTIONS

DNA SOLUTIONS is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cue Biopharma

Cue Biopharma™ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient`s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform™. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

Twentyeight-Seven Therapeutics

Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases.

Marengo Therapeutics

Marengo Therapeutics is pioneering an entirely new way to activate the body`s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay.

TCR2

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.